Yes, you can absolutely add a GLP-1 receptor agonist to your current regimen of long-acting insulin and Jardiance (empagliflozin).
Adding a GLP-1 receptor agonist to basal insulin and an SGLT-2 inhibitor like Jardiance is not only safe but strongly recommended by current guidelines, particularly if you have cardiovascular disease, are at high cardiovascular risk, or need better blood sugar control. 1, 2
Why This Combination Makes Sense
The 2025 American Diabetes Association guidelines explicitly support combining GLP-1 receptor agonists with both basal insulin and SGLT-2 inhibitors 2. These three medication classes work through completely different mechanisms:
- Jardiance (SGLT-2 inhibitor): Removes glucose through urine, protects heart and kidneys
- Long-acting insulin: Provides baseline glucose control
- GLP-1 receptor agonist: Stimulates insulin release when glucose is high, suppresses appetite, slows stomach emptying
When You Should Prioritize Adding a GLP-1 Agonist
You should strongly consider adding a GLP-1 agonist if:
- You have established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) 1, 2
- You're at high risk for stroke 1
- Your A1C remains above goal despite current medications 2
- Weight loss is an important treatment goal 1
The 2024 American College of Physicians guidelines specifically state that GLP-1 agonists reduce all-cause mortality, major cardiovascular events, and stroke 1.
Important Medication Adjustments
Critical: When you add a GLP-1 agonist, your long-acting insulin dose should be reduced by approximately 20% if your A1C is ≤8% 2, 3. This prevents hypoglycemia since both medications lower blood sugar. Your doctor must make this adjustment.
The guidelines explicitly warn: "When adding an SGLT-2 inhibitor or a GLP-1 agonist results in adequate glycemic control, clinicians should reduce or discontinue existing treatment with sulfonylureas or long-acting insulins due to increased risk for severe hypoglycemia" 1.
Evidence Supporting This Triple Combination
Multiple studies demonstrate that:
- Adding a GLP-1 agonist to basal insulin reduces A1C by 1-2% without significant weight gain 2
- The combination produces less hypoglycemia than adding mealtime insulin 4, 3
- Patients experience weight loss rather than weight gain 4, 3
- All-cause hospitalizations decrease compared to intensifying insulin alone 4
Recent evidence shows combining SGLT-2 inhibitors and GLP-1 agonists provides synergistic cardiovascular and metabolic benefits 5, 6. The combination improves A1C, body weight, and blood pressure more than either agent alone.
Practical Considerations
Fixed-ratio combination products (like iGlarLixi or IDegLira) combine basal insulin and a GLP-1 agonist in one injection, which may simplify your regimen 2, 7.
Common side effects of GLP-1 agonists include nausea, vomiting, and diarrhea, especially during the first few weeks 3. These typically improve with gradual dose titration.
Contraindications to avoid: Do not use GLP-1 agonists if you have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 8.
The Bottom Line
Current evidence strongly supports triple therapy with basal insulin, SGLT-2 inhibitors, and GLP-1 agonists in appropriate patients 5, 6. This combination addresses multiple pathophysiologic defects in type 2 diabetes while providing cardiovascular and kidney protection beyond glucose lowering alone. The key is proper insulin dose reduction when initiating the GLP-1 agonist to minimize hypoglycemia risk.